Industry landscapes
The companies, capital and talent shaping healthtech in Ireland. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
21 of 542 tracked companies have open roles.
143 of 542 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 276 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 33.7% of disclosed capital, while 73.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $113.08M | 40 | 18 |
| 2017 | $56.85M | 41 | 14 |
| 2018 | $425.64M | 43 | 25 |
| 2019 | $170.75M | 32 | 33 |
| 2020 | $212.2M | 48 | 29 |
| 2021 | $409.5M | 22 | 34 |
| 2022 | $291.66M | 20 | 26 |
| 2023 | $216.23M | 13 | 19 |
| 2024 | $211.71M | 7 | 12 |
| 2025 | $286.8M | 2 | 11 |
Share of all disclosed company funding.
331 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Vestra Partners.
Backed by Casdin Capital and Commonfund and others.
Backed by Polaris Partners and Sands Capital and others.
Backed by Montreux Equity Partners and Barry’s Tea.
Backed by MVM and Orbimed and others.
Backed by Illumina Ventures and HLM Venture Partners and others.
Backed by Orbimed and Montreux Equity Partners and others.
Backed by Medtronic and Gilde Healthcare and others.
Backed by Gilde Healthcare and Lightstone Ventures and others.
Backed by Haemonetics.
Backed by Life Sciences Partners and Andera Partners and others.
No reviewed exact national-ID connector has yet been qualified for Ireland; this is a checked implementation boundary, not evidence that filings are absent.
How the Ireland companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
54 of these companies (10%) publish at least one Android app — 115 apps in all, carrying 4.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Complete Anatomy - Learn in 3D3D4Medical | 2.4M | 3.3 | Medical |
| Dare: Anxiety & Panic AttacksDare Response | 938.3K | 4.8 | Health & Fitness |
| LetsGetChecked: Health TestsLetsGetChecked | 156.7K | 4.1 | Medical |
| Essential Anatomy 53D4Medical | 94K | 2.1 | Medical |
| سرهمبندی: بازی حدس کلمات فارسیCloudTree | 91K | 4.3 | Trivia |
| FitrWomanFitrWoman | 75.5K | 3.8 | Health & Fitness |
| OneTouch HealthOneTouch Health | 51.4K | — | Productivity |
| Logo Quiz: Guess Brands 2026CloudTree | 49.3K | 4.6 | Trivia |
| TCD ResearchNeureka (Entertainment Software) | 40K | 3.9 | Education |
| AIRE by FoodMarbleFoodMarble | 28.6K | 4 | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare It | 52 | 2.7M | Complete Anatomy - Learn in 3D 2.4M | |
| Disease Self Management | 56 | 1.4M | Dare: Anxiety & Panic Attacks 938.3K | |
| Fitness & Wellness Tech | 4 | 1M | FitrWoman 75.5K | |
| Healthcare Booking Platforms | 9 | 192.3K | LetsGetChecked: Health Tests 156.7K | |
| Artificial Intelligence | 3 | 64.5K | TCD Research 40K | |
| Ai In Healthcare | 2 | 64.5K | Neureka 24.4K | |
| Services For Healthcare Providers | 13 | 36.1K | T-Pro Dictate 26.1K | |
| Iot Applications | 2 | 7.4K | HealthBeacon Companion US 5.6K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 99 of 115 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
15 companies hiring · $2.22B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Galway-based medtech company Luminate Medical, which raised $21m.
The new investment in the business comes weeks after it secured a $441,437 grant from the Gates Foundation – the nonprofit NGO co-founded by billionaires Bill and Melinda Gates – to accelerate the development of an affordable HIV viral load test designed for use in low and middle-income countries.
HealthBeacon (2021).
NEW YORK – Irish diagnostic firm Trinity Biotech announced on Wednesday that it has entered into a $25 million standby equity purchase agreement with an affiliate of its financing partner Yorkville Advisors Global.
The parties entered into a definitive agreement on 22 October 2025 (as amended on 18 November 2025) which provided for the acquisition to occur by way of scheme of arrangement through the High Court of Ireland. Avadel Pharmaceuticals plc and Alkermes plc are each biopharmaceutical companies headquartered in Ireland. The transaction completed on 12 February 2026.
Ireland-based Smile Genius raising €850k to expand its digital platform connecting dental clinics and laboratories across the UK and Ireland.
GTS expertise secures £100 million funding for Middle East Glass Expertise provided by U.K. research and development organization Glass Technology Services helped secure a US$100 million finance package for Egypt’s Middle East Glass Manufacturing Company (MEG).
Bluedrop Medical, a Galway-based medtech company, has secured a €1m investment from Enterprise Ireland as the semi-state agency bolsters its backing for companies seeking to scale globally.
ProVerum secured €68.6 million to advance a minimally invasive urology treatment
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk‑reward sharing partnerships, today announced that it expects to receive up to $21 million in cash proceeds in connection with the acquisition of Vivasure, an Ireland‑based company pioneering next‑generation technology for percutaneous vessel closure, by Haemonetics Corporation (NYSE: HAE, “Haemonetics”), which closed on January 9, 2026.
Top 10 categories among 237 recorded events in the 24-month window.
2 companies with recorded IPO activity
IPO · Dublin2 reports
IPO · Nasdaq4 reports
9 tracked people moves
Promotion Vice President of Security Strategy
Appointment Vice President of Marketing
Promotion Vice President of Security Strategy
Departure Previously Senior Vice President of Strategy and Business Development, Covidien’s Senior Vice President of Strategy and Business Development
Appointment Non-Executive Director
Products, platforms and features in the recorded window
AI-native continuous glucose monitoring system
2 recorded customer wins
Customer: Healthcare diagnostics
Customer: respironics
1 companies with reported reductions
32 rolescost reduction
13 recorded events
approved for upstream manufacturingin‑country healthcare product regulatory authority
approvedWorld Health Organization (WHO)
approved for saleU.S. Food & Drug Administration
scheme of arrangement approvedIrish High Court
2 tracked suits
plan of arrangement under Section 193 of the Business Corporations Act (Alberta)Regulatory · Verdict
breach of contract, fraud, negligent misrepresentation, unjust enrichment, and violation oCivil ·
Reported company results in the recorded window.
Median across 24 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| alkermes→Avadel Pharmaceuticals ↗ | Completed | 2026-02-12 | Not stated in snapshot |
| Haemonetics Corporation→Vivasure Medical ↗ | Announced | 2026-01-12 | $21.0M |
| lundbeck→Avadel Pharmaceuticals ↗ | Announced | 2025-11-21 | Not stated in snapshot |
| H Lundbeck A/S→Avadel Pharmaceuticals ↗ | Announced | 2025-11-15 | Not stated in snapshot |
| h. lundbeck a/s→Avadel Pharmaceuticals ↗ | Announced | 2025-11-14 | Not stated in snapshot |
| Lanas Healthcare Technology→Clanwilliam Group ↗ | Completed | 2025-09-12 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
20 postings in the preceding 12 months. The full 101-posting snapshot covers 76 employers.
0 tracked postings mention remote work.
13 postings specify a level.
Top skills across 101 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| LetsGetChecked ↗ | 570 |
| GC Aesthetics ↗ | 259 |
| Utah Medical Products ↗ | 221 |
| Mainstay Medical ↗ | 136 |
| Oneview Healthcare ↗ | 90 |
| Trinity Biotech ↗ | 78 |
| Altratech ↗ | 75 |
| Biotrin International ↗ | 75 |
261 founders and chief executives across 203 companies.
Ex-NuVasive. University of California, Berkeley BA, Stanford University JD
Chief Executive Officer Avadel Pharmaceuticals plc, Ex-Executive In Residence Linden Capital, President & CEO Lumara Health Partners .
Ex-The Health Partnership, KBC Bank Ireland. Dublin Business School LLB, University College Dublin
Ex-Cerballiance, Novescia, GE Healthcare. Paris-Sud University 1995
Enterprise, ex-Healthbeacon, ex-Irish Medtech Association, Stanford University Graduate School of Business, 2011
Proverum, ex-Seroba Life Sciences, ex-Bioinnovate, Trinity College Dublin, 2012
Ex-CEO Zerusa, Boston Scientific, Ciba Additives. Auburn University MBA 1996
Ex- GlaxoSmithKline. The University of Manchester BA
St Vincent’s University Hospital and Blackrock Clinic. Trinity College MSc, Royal College of Surgeons in Ireland PhD 2001
Founder MedInnovate, ex-Co-Founder i2Sense, CureFab. Technical University of Munich 2015
Luminate Medical, ex-University Of Galway, ex-Hrb Clinical Research Facility Galway, National University of Ireland, Galway, 2018
Ex-Silicon Labs, Founder & CEO ChipSensors, Cratlon, Analog Devices.
24 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
203,082 articles in the measured 12-month window.
Healthtech coverage across Ireland · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 28,394 |
| 2021Q3 | 57,103 |
| 2021Q4 | 27,056 |
| 2022Q1 | 31,102 |
| 2022Q2 | 27,778 |
| 2022Q3 | 25,959 |
| 2022Q4 | 30,803 |
| 2023Q1 | 32,215 |
| 2023Q2 | 34,183 |
| 2023Q3 | 31,903 |
| 2023Q4 | 28,694 |
| 2024Q1 | 32,481 |
| 2024Q2 | 34,558 |
| 2024Q3 | 31,887 |
| 2024Q4 | 30,186 |
| 2025Q1 | 41,090 |
| 2025Q2 | 25,398 |
| 2025Q3 | 112,675 |
| 2025Q4 | 24,441 |
| 2026Q1 | 32,573 |
Article volume measures coverage, not market sales.
358 recorded company events across 34 companies; percentages use that event total.
Healthtech coverage across Ireland · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Ireland
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| study overseas | 414 | 200 | 107% |
| overseas study | 372 | 181 | 106% |
| semester abroad | 355 | 172 | 106% |
| stock performance | 318 | 181 | 76% |
| sports legislation | 193 | 90 | 114% |
| international programs | 186 | 97 | 92% |
| border enforcement practices | 170 | 33 | 415% |
| bowl game matchups | 163 | 80 | 104% |
| comex gold analysis | 157 | 77 | 104% |
| world cup women | 154 | 88 | 75% |
| hurling in irish literature | 400 | 851 | -53% |
| odi world cup | 255 | 790 | -68% |
| icc world cup | 227 | 730 | -69% |
| odi tactics | 336 | 691 | -51% |
| historical matches hurling | 310 | 677 | -54% |
Healthtech coverage across Ireland
mark rule gaelic football, odi world cup, limited overs cricket
39.2% critical · 33.0% positivehurling in irish literature, historical matches hurling, county rivalries hurling
30.8% critical · 41.0% positivetax policy execution, tax expenditure oversight, gdp growth rate
34.1% critical · 44.8% positiveHealthtech coverage across Ireland. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Researchers examine factors and methods that affect the ability of health systems to remain functional under stress.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Papers discuss obstacles in discovering and repurposing drugs for multifactorial diseases and oncology.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Studies highlight difficulties in implementing eHealth tools and achieving universal coverage through digital means.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Works identify practical and regulatory challenges that limit telemedicine and telerehabilitation effectiveness.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Research points to diagnostic, biomarker, and resistance problems hindering personalized cancer treatments.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Authors analyze safety concerns and the need for updated regulatory frameworks for wearable and moderate‑risk devices.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Investigations assess how COVID‑19 spikes have stressed telehealth services and affected patient‑provider interactions.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Cautionary papers stress the need for rigorous assessment of telehealth’s impact on health outcomes and satisfaction.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Studies warn of technical, logistical, and quality‑assessment challenges when deploying e‑health tools in diverse settings.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Research highlights uncertainties in biomarker validation and predictive modeling for new pharmacological agents.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Authors caution about efficacy, adoption, and user experience issues in digital psychological and aging‑related programs.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Papers explore clinician perspectives and barriers that emerged during pandemic‑driven telemedicine expansion.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Works discuss limited awareness, understanding, and practical integration of personalized oncology approaches.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Research raises ethical, interpretability, and workflow challenges when applying artificial intelligence to precision health.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Opportunities focus on improving clinical usability and evidence‑based models for digital transformation in care.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Papers highlight computational screening and docking methods that accelerate discovery of novel therapeutics.
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Research showcases how molecular docking and chemical‑space exploration can streamline target identification.
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Studies present telemedicine as a means to extend physical‑therapy and palliative services to remote patients.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Works explore leveraging pharmacogenomics and deep learning to tailor treatments for complex diseases.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Research emphasizes remote patient monitoring and IoT integration to support continuous health tracking.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Papers discuss bioinformatics approaches to identify circulating tumor markers for individualized oncology care.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 37.5% |
| Problem-identifying | 29.0% | 9.5% |
| Descriptive | 18.8% | 17.4% |
| Breakthrough | 12.7% | 26.4% |
| Cautionary | 6.4% | 4.3% |
| Comparative | 2.5% | 3.9% |
| Critical | 0.9% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
67.0% across the displayed hubs
9 companies hiring · $2.0B disclosed funding
Explore companies in Dublin ↗
15.7% across the displayed hubs
6 companies hiring · $546.1M disclosed funding
Explore companies in Galway ↗
8.1% across the displayed hubs
0 companies hiring · $69.5M disclosed funding
Explore companies in Cork ↗
3.3% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Limerick ↗
1.5% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Sligo ↗
1.5% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Mallow ↗
1.5% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Waterford ↗
1.3% across the displayed hubs
0 companies hiring · $798.5K disclosed funding
Explore companies in Bray ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 2 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗